Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP; Note: local surgery of isolated lesions for palliative intent is acceptableXx_NEWLINE_xXIncomplete recovery from any surgeryXx_NEWLINE_xXMajor surgery within 28 days of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXPatients must begin treatment as outlined in the protocol within 36 days of definitive surgery (day of surgery is day 0; definitive surgery includes second surgeries to resect residual tumor)Xx_NEWLINE_xXNo contraindication for surgeryXx_NEWLINE_xXPatients must be adequately recovered from surgery at the time of randomizationXx_NEWLINE_xXThe minimum time requirement between date of surgery and randomization must be at least 4 weeks (28 days)Xx_NEWLINE_xXPatients must not have received any major surgery or immunotherapy within 28 days prior to registrationXx_NEWLINE_xXPatients may have received prior surgery; at least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgeryXx_NEWLINE_xXNone of the following conditions:\r\n* Grade 3 or greater infection, or infection requiring intravenous systemic treatment within 28 days prior to registration; patients should be off antibiotics at the time of registration.\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days prior to registration\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days prior to registration\r\n* History of surgery as follows:\r\n** Major surgery (as an example, surgery requiring anesthesia and a > 24 hour hospital stay) within 3 months prior to registration, with wound healing at least 28 days prior to registration\r\n** Minor surgery within 28 days prior to registration with complete wound healing at least 10 days prior to registration\r\n** Minor procedures within 7 days prior to registration such as thoracentesis, paracentesis, or 18 g or smaller needle biopsy of tumor\r\n** Patients with clinically relevant ongoing complications from prior surgery are not eligibleXx_NEWLINE_xXNo major surgery within 21 days of registration with stabilization or resolution of surgical adverse eventsXx_NEWLINE_xXNo major surgery =< 14 days prior to registrationXx_NEWLINE_xXNo major surgery within 28 days prior to randomizationXx_NEWLINE_xXNo major surgery within 28 days prior to registrationXx_NEWLINE_xXSurgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered adequately from the effects of surgeryXx_NEWLINE_xXNo major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior to registration (with the exception of intravenous access placement, e.g. Hickman or peripherally inserted central catheter [PICC])Xx_NEWLINE_xXPatients must be enrolled on ALTE07C1 prior to enrollment on ACNS1422\r\n* Patients must be enrolled within 36 days of definitive diagnostic surgery (day 0)\r\n** Note: patients must begin treatment within 36 days of definitive surgeryXx_NEWLINE_xXPatient must have not had any major surgery or radiation within 28 days prior to step 1 registration; diagnostic thoracotomies and laparoscopies are not considered major surgeriesXx_NEWLINE_xXSTEP 2: SURGERYXx_NEWLINE_xXStep 1 registration must occur within 180 days of the initial surgery; within this 180 day interval, a second surgery is permitted in order to achieve GTR, but even with a second surgery, step 1 registration must occur within 180 days of the initial resectionXx_NEWLINE_xXMajor surgery within 30 days prior to enrollment.Xx_NEWLINE_xXPatient has had major surgery within 14 days prior to treatment start or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXParticipants must have recovered adequately from any toxicity and/or complications from major surgery prior to starting therapyXx_NEWLINE_xXMajor surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXEligible for surgery with curative intentXx_NEWLINE_xXMajor bowel surgery which in the opinion of the Investigator should exclude the patientXx_NEWLINE_xXPatients who cannot undergo surgeryXx_NEWLINE_xXHistory of major surgery within 30 days prior to trial initiationXx_NEWLINE_xXPatients who have undergone major surgery or trauma within 28 days prior to the first dose of investigational product and/or present with any non-healing wound, fracture, or ulcer are NOT eligible for participation; procedures such as catheter placement not considered to be major surgeryXx_NEWLINE_xXMajor surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)Xx_NEWLINE_xXAll patients who have surgery performed must have a cranial MRI pre-operative and post-operative (should be done within 72 hours of surgery or within 21 days following surgery)Xx_NEWLINE_xXPatient must have recovered from the surgeryXx_NEWLINE_xXNote: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMajor surgical procedures not permitted </=28 days prior to enrollment. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before enrollment. In all cases the patient must be sufficiently recovered and stable before treatment administrationXx_NEWLINE_xXMajor surgery within 28 days of first dose AMG 757Xx_NEWLINE_xXMajor surgery ?28 days or major radiation therapy ?14 days prior to enrollment.Xx_NEWLINE_xXRecovered from any previous surgery and no history of major surgery within the last 28 days prior to start of study drugXx_NEWLINE_xXNo major surgery within 30 days of first study treatment.Xx_NEWLINE_xXMajor surgery within 2 weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery)Xx_NEWLINE_xXMajor surgery within 28 days before the start of trial treatment (excluding prior diagnostic biopsy); or use of any investigational drug within 28 days before the start of trial treatment.Xx_NEWLINE_xXMajor surgery requiring general anesthesia within 14 days before the first dose of any study drug or a scheduled surgery during study period; (placement of a central line or port-a-catheter is acceptable within this time frame and does not exclude the patient)Xx_NEWLINE_xXMajor surgery =< 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXMajor surgery within 28 days of study day 1 with the exception of biopsy and insertion of central venous catheter.Xx_NEWLINE_xXMajor surgery, radiation therapy, or systemic anti-cancer therapy within 28 days of starting study treatment.Xx_NEWLINE_xXMajor surgery within 28 days before Cycle 1 Day 1Xx_NEWLINE_xXPatient has had major surgery or insufficient recovery from surgical-related trauma or wound healing within 14 days of study day 1Xx_NEWLINE_xXMajor surgery within 28 days of the first dose of study drugXx_NEWLINE_xXPatients who have undergone major surgery within 28 days or subcutaneous venous access device placement within 7 days prior to study enrollmentXx_NEWLINE_xXHave had recent major surgery within a minimum 4 weeks prior to starting study treatment; minor surgeries such as surgical placement for vascular access are not exclusionaryXx_NEWLINE_xXSAFETY RUN-IN: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSurgery, unless documented contraindicationXx_NEWLINE_xXHave had major surgery or bone fracture within 28 days before first dose of study treatmentXx_NEWLINE_xXMajor surgery within 3 weeks of starting study treatment; there is no minimum time requirement for minor procedures such as biopsy or vascular access placementXx_NEWLINE_xXTreatment with major surgery (requiring general anesthesia) within one month prior to study entryXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXMajor surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXParticipants who underwent major surgery (including craniotomy) or significant traumatic injury within 28 days prior to initiating therapy; baseline MRIs for participants who underwent salvage surgery must be obtained within 14 days of registration (similar to other patients who do not have surgery) and there must be measurable diseaseXx_NEWLINE_xXSuccessful Avatar engraftment from initial surgery or surgery/biopsy of recurrent cancer with successful expansion and treatment outcome of Avatar therapyXx_NEWLINE_xXMajor surgery within 28 days prior to initiation of study drug.Xx_NEWLINE_xXMajor surgery within 12 weeks before the first dose of cabozantinib; complete wound healing from major surgery must have occurred 1 month before the first dose of cabozantinib; minor surgery (including uncomplicated tooth extractions) is allowed if it occurred 28 days before the first dose of cabozantinib with complete wound healing at least 10 days before the first dose of cabozantinib; subjects with clinically relevant ongoing complications from prior surgery are not eligibleXx_NEWLINE_xXMajor surgery less than 28 days prior to study entry.Xx_NEWLINE_xXMajor surgery within 14 days prior cycle 1, day 1Xx_NEWLINE_xXMajor surgery within 28 days prior to initiating therapyXx_NEWLINE_xXMajor surgery within 21 days prior to first doseXx_NEWLINE_xXPatients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia but excluding a procedure for insertion of central venous access)Xx_NEWLINE_xXPatients who may require major surgery during the course of the studyXx_NEWLINE_xXMajor surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligibleXx_NEWLINE_xXMajor surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e. larger than that required for placement of central venous access, percutaneous feeding tube, or biopsy) within 28 days of the first dose of study drugXx_NEWLINE_xXMinor surgical procedures within 7 days of baseline, or not yet recovered from prior surgery.Xx_NEWLINE_xXParticipants who have undergone major surgery within 14 days of starting the study treatment, or participants who have not recovered to baseline status from the effects of major surgery received more than 14 days prior.Xx_NEWLINE_xXMajor surgery within 28 days of day 1 (does not include central venous access or shunts)Xx_NEWLINE_xXHas had major surgery within 21 days before cycle 1, day 1Xx_NEWLINE_xXParticipant had major surgery within 28 days prior to Study Day 1.Xx_NEWLINE_xXMust be a candidate for salvage surgeryXx_NEWLINE_xXIf subject underwent major surgery they must have recovered adequately from the toxicity and/or complications from the procedure prior to starting therapyXx_NEWLINE_xXPatients with a known bacterial infection present at the time of surgery or who received antimicrobial therapy within 7 days prior to surgeryXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXParticipants who have not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapyXx_NEWLINE_xXMajor surgery within 28 days prior to first dose of protocol therapyXx_NEWLINE_xXMinor surgery/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapyXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXIf had major surgery, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to study registrationXx_NEWLINE_xXParticipants must be >= 28 days from any major surgeryXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXParticipants who have undergone major surgery within 14 days of starting the study treatment, or participants who have not recovered to baseline status from the effects of major surgery received more than 14 days priorXx_NEWLINE_xXHas not fully recovered from any effects of major surgery, and is free of significant detectable infection. Surgeries that required general anesthesia must be completed >2 weeks before first study drug administration. Surgery requiring regional/epidural anesthesia must be completed >72 hours before first study drug administration and participants should be recovered.Xx_NEWLINE_xXSurgery within 4 weeks prior to study registration except for minor procedures. NOTE: Hepatic biliary stent placement is allowed. NOTE: Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.Xx_NEWLINE_xXOther clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; participants with known hepatitis B infection should be screened for active disease prior to study participation; participants with known hepatitis C infection must not be actively receiving treatment for the infection\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryXx_NEWLINE_xXNot recovered from AEs and/or complications from major surgery prior to first doseXx_NEWLINE_xXNo history of major surgery =< 28 days of registrationXx_NEWLINE_xXSurgical patients must have tumor that needs to be removed/debulked and is accessible for the neurosurgeon; need for surgery must be such that the patient can take drug for at least 10 days to maximum 14 days before surgeryXx_NEWLINE_xXPatients who are not candidates for major abdominal surgery due to known medical comorbiditiesXx_NEWLINE_xXMajor surgery (eg, requiring general anesthesia) within 3 weeks before screening, or has not fully recovered from prior surgery (ie, unhealed wound); Note: subjects with planned surgical procedures to be conducted under local anesthesia may participateXx_NEWLINE_xXMajor surgery within 2 months prior to enrollment or minor surgery within 7 days of the first day of treatmentXx_NEWLINE_xXMajor thoracic or abdominal surgery from which the patient has not sufficiently recovered yetXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXNot candidate for curative surgery, is unfit for surgery, or does not wish to undergo curative surgeryXx_NEWLINE_xXPatients who have had major surgery or have insufficient recovery from surgical-related trauma or wound healing within 14 days from study day 1Xx_NEWLINE_xXPrior chemotherapy and/or immunotherapy within 14 days before enrollment; major surgery within 14 days before enrollment and minor surgery within 7 days prior to cycle 1 day 1Xx_NEWLINE_xXNot eligible for surgeryXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXRecovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment; endoscopic debridement of RRP lesions is NOT considered a major surgeryXx_NEWLINE_xXMajor hemorrhagic event within 28 daysXx_NEWLINE_xXMajor surgery =< 14 days before study registrationXx_NEWLINE_xXMajor surgery within 28 days prior to the first study treatmentXx_NEWLINE_xXSubject has had major surgery within 28 days prior to study day 1Xx_NEWLINE_xXMajor surgery within 28 days of study day 1 with the exception of biopsy and long line insertionXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXMajor surgery within 28 days prior to the start of BGB324 - excluding skin biopsies and procedures for insertion of central venous access devicesXx_NEWLINE_xXMajor surgery, excluding skin biopsies and procedures for insertion of central venous access devices, within 28 days prior to the start of COTI-2.Xx_NEWLINE_xXMajor surgery within 14 days before randomization.Xx_NEWLINE_xXPatients with major surgery within 28 days prior to trial enrollmentXx_NEWLINE_xXPatients may not have had major surgery within 10 days of enrollment, or minor surgery within 7 days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physicianXx_NEWLINE_xXMajor surgery within 14 days before enrollment; biopsies and line placement procedures are not exclusion criteriaXx_NEWLINE_xXAny major surgeries within 28 days.Xx_NEWLINE_xXMajor surgery =< 14 days prior to study registrationXx_NEWLINE_xXMajor surgery within 28 days prior to treatment or major surgery planned during the next 6 monthsXx_NEWLINE_xXMajor surgery within 1 month prior to enrollmentXx_NEWLINE_xXPatients with a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeonXx_NEWLINE_xXMajor surgery must be completed greater than 28 days prior to registration for protocol therapy and healed surgical incision is requiredXx_NEWLINE_xXHas had major surgery within 21 days before cycle 1, day 1.Xx_NEWLINE_xXEXCLUSION - DURVALUMAB DRUG-SPECIFIC: Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of durvalumab. \r\n* Note: Local surgery of isolated lesions for palliative intent is acceptable per investigator discretion.Xx_NEWLINE_xXMajor surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. \r\n* Note: Local surgery of isolated lesions for palliative intent is acceptable.Xx_NEWLINE_xXHas not had major surgery within 28 days prior to starting study treatment. Central venous access surgeries and/or placements would not be considered as major surgery.Xx_NEWLINE_xXMajor surgery as determined by the investigator within 28 days before the start of trial treatment (prior diagnostic biopsy is permitted).Xx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXStable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections or major surgery within 28 days prior to study enrollmentXx_NEWLINE_xXMajor surgery ? 14 days prior to study registrationXx_NEWLINE_xXPRIOR THERAPY OR SURGERYXx_NEWLINE_xXMajor surgery or radiation therapy within 14 days before study drug administrationXx_NEWLINE_xXMajor surgical procedure (as defined by the investigator) within 28 days prior to the first dose of ipilimumab, (IP). \r\n* Note: Local surgery of isolated lesions for palliative intent is acceptable.Xx_NEWLINE_xXPatients must have recovered from the effects of surgery per treating physician’s judgment; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment; for core or needle biopsy, a minimum of 14 days must have elapsed prior to the day of protocol treatmentXx_NEWLINE_xXHistory of major surgery within 3 weeks or minor surgery within 1 week of roflumilast administration; major surgery includes, for example, any open or laparoscopic entry into a body cavity, or operative repair of fracture; minor surgery includes, for example, open surgical biopsy of palpable/superficial lymph node, or placement of vascular access deviceXx_NEWLINE_xXMajor surgery (requiring general anesthesia) within 30 days prior to initiation of therapyXx_NEWLINE_xXMajor surgery over the target area (excluding placement of vascular access) <21 days from beginning of the study drug or minor surgical procedures <7 daysXx_NEWLINE_xXRecovery of reversible effects of prior surgery (i.e., incisional pain, wound drainage) to grade >= 1, and at least 4 weeks from prior surgery to treatment startXx_NEWLINE_xXMajor surgery as determined by the investigator within 28 days before the start of trial treatment (prior diagnostic biopsy is permitted).Xx_NEWLINE_xXMajor surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study medication. Note: Local surgery of isolated lesions for palliative intent is acceptable.Xx_NEWLINE_xXMajor surgery within 28 days prior to the first drug administration (minimally invasive procedures such as diagnostic biopsies are permitted)Xx_NEWLINE_xXMajor surgery within 28 days of registrationXx_NEWLINE_xXMajor surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery.Xx_NEWLINE_xXSurgery unable to be performed between 1 – 3 days after radiosurgeryXx_NEWLINE_xXMajor surgery within 28 days of enrollment.Xx_NEWLINE_xXMajor surgery within 14 days before the first dose of any study drug or a scheduled surgery during the study periodXx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 21 daysXx_NEWLINE_xXMajor surgery within 28 days prior to first dose of study drugXx_NEWLINE_xXMajor surgery (requiring general anesthesia) within 3 months prior to dosing.Xx_NEWLINE_xXMajor surgery within 28 days prior to randomization.Xx_NEWLINE_xXMust have recovered from effects of surgery, postoperative infection and other complications of surgeryXx_NEWLINE_xXMajor surgery within 21 days of starting protocol treatmentXx_NEWLINE_xXOther clinically significant disorders such as: i. active infection requiring systemic antibiotic treatment within 14 days before the first dose of study treatment ii. serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment iii. history of organ transplant iv. concurrent uncompensated hypothyroidism or thyroid dysfunction (thyroid-stimulating hormone [TSH] above 10) within 28 days before the first dose of study treatment v. major surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.Xx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 21 daysXx_NEWLINE_xXMajor surgery and surgery for brain metastases within 28 days prior to screening start; of note, intravenous port placement is not considered as a major surgeryXx_NEWLINE_xXHas newly diagnosed disease (no prior chemotherapy, radiation or surgery with curative intent for this sarcoma diagnosis – prior surgery for diagnostic purposes are allowable)Xx_NEWLINE_xXPatients must not have had chemotherapy, major surgery, monoclonal antibody therapy or experimental therapy within the 21 days prior to the start of ibrutinib administrationXx_NEWLINE_xXMajor surgery within 14 days before the first dose of any study drug or a scheduled surgery during study periodXx_NEWLINE_xXMajor surgery within 12 weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment; all clinically relevant ongoing complications from prior surgery should be resolved before the first dose of study treatmentXx_NEWLINE_xXMajor surgery within the past 2 monthsXx_NEWLINE_xXHad hospitalization for infection or major surgery (e.g., requiring general anesthesia) within 2 weeks before enrollment or have not fully recovered from surgery; Note: subjects with surgical procedures conducted under local anesthesia may participateXx_NEWLINE_xXNo major surgery within 14 days of start of study treatmentXx_NEWLINE_xXMajor surgery within 2 months before enrollment; complete healing from major surgery must have occurred 1 month before enrollment; complete healing from minor surgery (eg, simple excision, tooth extraction) must have occurred at least 7 days before enrollment; subjects with clinically relevant complications from prior surgery are not eligibleXx_NEWLINE_xXPatients who have had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 2 weeks prior to starting study drug or who have not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedureXx_NEWLINE_xXMajor surgery within 28 days of starting study treatmentXx_NEWLINE_xXIf received major surgery, not recovered adequately from the toxicity and/or complications from the intervention prior to starting the studyXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury (injury requiring > 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that are expected to require major surgery, other than cytoreductive nephrectomy +/- retroperitoneal lymph node dissection, during the course of the study.Xx_NEWLINE_xXPrior systemic cytotoxic therapy, antineoplastic biologic therapy, or major surgery within 28 days of first dose of study medicationXx_NEWLINE_xXSubject has had major (per Investigator discretion) surgery, with the exception of tumor resection, within 21 days from first dose of study drug.Xx_NEWLINE_xXPrior biliary bypass surgeryXx_NEWLINE_xXMajor surgery =< 14 days prior to starting study treatment or who have not recovered from side effects to < grade 2 CTCAEXx_NEWLINE_xXPituitary surgery within six monthsXx_NEWLINE_xXPatients must have recovered from the effects of surgery; there must be a minimum of 21 days from the day of surgery to the day of protocol treatmentXx_NEWLINE_xXCentral line placement or subcutaneous port placement is not considered major surgery but must be placed at least 2 days prior to study drug administration.Xx_NEWLINE_xXIf subjects received major surgery they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapyXx_NEWLINE_xXMajor surgery (including opening of the abdomen, chest, or skull) within 21 days of the first dose of study drug.Xx_NEWLINE_xXMajor surgery, radiotherapy or infection requiring therapy within 14 days of starting treatmentXx_NEWLINE_xXMajor surgery within 12 weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligibleXx_NEWLINE_xXMajor surgical procedure (as defined by the investigator) within 28 days prior to the first dose of durvalumab or tremelimumab. Note: Local surgery of isolated lesions for palliative intent is acceptable.Xx_NEWLINE_xXMajor surgery =<14 days prior to registrationXx_NEWLINE_xXMajor surgical procedure within 28 days prior to the first dose of durvalumab; local surgery of isolated lesions for palliative intent is acceptableXx_NEWLINE_xXPrior surgery: patients may not have had major surgery within 28 days of enrollment, or minor surgery within 7 days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physicianXx_NEWLINE_xXPatients must have measurable lesion(s) and one or more of the following criteria:\r\n* Failure of surgery to control disease (i.e. positive margins or recurrence of HSIL after surgery)\r\n* Multifocal or extensive disease for which surgery would result in major deformity that is not be acceptable to the patient\r\n* Disease for which surgery would have a risk of functional impairment that is not be acceptable to the patient (i.e. involve partial or complete excision of the clitoris, anus, vagina, or urethra)Xx_NEWLINE_xXMajor surgery within 28 days prior to start of study treatment and failure to have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study treatment.Xx_NEWLINE_xXMajor surgery within 28 days prior to day 1 of study treatment from which the patient has not completely recoveredXx_NEWLINE_xXUndergone major surgery within 14 days of the initial dose of study drugXx_NEWLINE_xXMajor surgery (eg, nephrectomy) less than 28 days prior to the first dose of study drugXx_NEWLINE_xXIf subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention per clinical discretion of the investigator prior to starting therapyXx_NEWLINE_xXMajor surgery other than diagnostic surgery within 28 days of Study Day 1Xx_NEWLINE_xXMajor surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement are not considered to be major surgery)Xx_NEWLINE_xXMajor surgery (excluding skin biopsies and procedures for insertion of central venous access devices) within 2 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery (including breast surgery) within < 30 days of starting treatment or received chemotherapy, investigational agents, or other cancer therapy < 14 days prior to the initiation of investigational products (except adjuvant endocrine therapy)Xx_NEWLINE_xXSubject has had major surgery within 14 days prior to registration or has not recovered from major side effects of the surgery (tumor biopsy is not considered as major surgery).Xx_NEWLINE_xXPatient has had major surgery (e.g., intra­thoracic, intra­abdominal or intra­pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video­-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these proceduresXx_NEWLINE_xXScheduled for major surgery after baseline;Xx_NEWLINE_xXAny major surgery within 21 days prior to enrollmentXx_NEWLINE_xXPatient has had major surgery or insufficient recovery from surgical-related trauma or wound healing within 14 days of study day 1Xx_NEWLINE_xXSubject not a candidate for surgery;Xx_NEWLINE_xXOnly for subjects enrolled in Arm 1 - Neratinib and everolimus: Major surgery =< 28 days prior to treatment with everolimus.Xx_NEWLINE_xXMajor surgery (eg, nephrectomy) less than 28 days prior to the first dose of study drugXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXPrior major surgery or gastrointestinal perforation within 28 days of enrollmentXx_NEWLINE_xXEmergency surgeryXx_NEWLINE_xXSubject who has not recovered from the effects of any major surgery prior to initial treatmentXx_NEWLINE_xXAny patient who has had a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeonXx_NEWLINE_xXMajor surgery (requiring general anesthesia) within 3 months or minor surgery (excluding biopsies conducted with local/topical anesthesia) or gamma knife treatment within 14 days (with adequate healing) of administration of any study drug.Xx_NEWLINE_xXMajor surgery: only patients who are not anticipated to need major surgery within the next 3 months of enrollment are eligibleXx_NEWLINE_xXHistory of major surgery as follows:\r\n* Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n* Minor surgery within 1 months of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complicationsXx_NEWLINE_xXIn addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryXx_NEWLINE_xXMajor surgery within 14 days of registration and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXMajor surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy),within 28 days prior to randomization or anticipated surgery during the study periodXx_NEWLINE_xXTreatment must be initiated >= 14 days and < 6 weeks from surgeryXx_NEWLINE_xXPatients with major surgery within 30 days prior to entering the studyXx_NEWLINE_xXMajor surgery =< 14 days prior to registrationXx_NEWLINE_xXMajor surgery =< 28 days prior to registration; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMajor surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatmentXx_NEWLINE_xXMajor surgery within 14 days before the first dose of any study drug or a scheduled surgery during study periodXx_NEWLINE_xXMajor surgery within 14 days prior to starting study drug or has not recovered from surgical complications (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXMajor surgery* within 28 days before enrollment.Xx_NEWLINE_xXWithin 28 days before first dose of avelumab: anti-cancer treatment, major surgery requiring general anesthesia, or the use of any investigational agentXx_NEWLINE_xXMajor surgery within 1 month prior to enrollmentXx_NEWLINE_xXHad major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgeryXx_NEWLINE_xXHas had any major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgeryXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXSubjects who within 14 days prior to randomization have had major surgery or a lumbar puncture (or epidural steroid injection);Xx_NEWLINE_xXMajor surgery within 28 days prior to the start of BGB324, excluding skin biopsies and procedures for insertion of central venous access devicesXx_NEWLINE_xXMajor surgery =< 14 days prior to registrationXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXMajor surgery within 12 weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligibleXx_NEWLINE_xXParticipant has had at least 4 weeks of postoperative recovery from surgery prior to enrollment to ensure complete wound healing; participants with bowel resections at surgery should begin protocol at least 42 days after surgeryXx_NEWLINE_xXAt least 21 days have passed since major surgeryXx_NEWLINE_xXPrevious surgery is permitted provided that a minimum of 28 days (4 weeks) have elapsed between any major surgery and date of registration, and that wound healing has occurredXx_NEWLINE_xXMajor surgery within 30 days prior to the start of study medication.Xx_NEWLINE_xXAt least 30 days from major surgery before study enrollment, with full recoveryXx_NEWLINE_xXPrior major surgery must be completed at least 4 weeks before study drug administration; prior minor surgery must be completed at least 1 week before study drug administration and subjects should be recovered; percutaneous biopsies should be completed at least 10 days prior to study drug administrationXx_NEWLINE_xXMajor surgical procedure (as defined by the principal investigator [PI] or co-PIs within 28 days prior to the first dose of durvalumab and tremelimumab or still recovering from prior surgeryXx_NEWLINE_xXMajor surgery (excluding lymph node biopsy) within 28 days prior to randomization.Xx_NEWLINE_xXPrevious treatment with surgery, radiation, chemotherapy, targeted agents are allowed provided that: \r\n* Chemotherapy/major surgery was administered > 14 days before the start nivolumab\r\n* Minor surgery, radiation, or any targeted agents were administered > 7 days before the start of nivolumabXx_NEWLINE_xXMajor thoracic or abdominal surgery from which the patient has not sufficiently recovered yetXx_NEWLINE_xXMajor surgery within 30 days prior to start of treatmentXx_NEWLINE_xXMajor surgical procedure within 28 days prior to the first dose of IP; Note: local surgery of isolated lesions for palliative intent is acceptableXx_NEWLINE_xXThe patient has undergone major surgery within 28 days prior to enrollment, or subcutaneous venous access device placement within 7 days prior to enrollmentXx_NEWLINE_xXMajor surgery (e.g. intra-abdominal, intra-thoracic or intra-pelvic) within 4 weeks prior to starting study treatment or lack of recovery from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these proceduresXx_NEWLINE_xXAdequate recovery from all recent surgery is required. At least 21-days must have elapsed from the time of any major surgery, including craniotomy/tumor resection. Patients must have recovered from all surgery-related toxicities to Grade 1 or less.Xx_NEWLINE_xXPrior surgery to the same levels of spineXx_NEWLINE_xXMajor surgery =< 14 days before study registrationXx_NEWLINE_xXPatients who have had major surgery within 21 days before cycle 1, day 1Xx_NEWLINE_xXIf subject underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMajor surgery other than diagnostic surgery within 28 days of Study Day 1Xx_NEWLINE_xXMajor surgery =< 28 days prior to registrationXx_NEWLINE_xXIf subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (all surgical wounds must be fully healed); for the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedureXx_NEWLINE_xXNo prior definitive surgery for HNSCCXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 14 daysXx_NEWLINE_xXMajor surgery within 28 days prior to C1D1.Xx_NEWLINE_xXHas had major surgery within 21 days before cycle 1, day 1Xx_NEWLINE_xXThe patient has undergone major surgery within 28 days prior to enrollment, or subcutaneous venous access device placement within 7 days prior to enrollmentXx_NEWLINE_xXPatient has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these proceduresXx_NEWLINE_xXMajor surgery within 28 days prior to study registration or those patients who have not recovered adequately from prior surgeryXx_NEWLINE_xXMajor surgery (such as GI surgery) within 6 weeks of enrollment; however, subjects who have had a nephrectomy may be enrolled 4 weeks after surgery, providing there are no wound-healing complications; subjects with clinically relevant ongoing complications from prior surgery are not eligible; the following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental proceduresXx_NEWLINE_xXHave undergone a major surgery (excluding minor procedures, e.g. placement of vascular access, biopsy, etc.) < 6 months prior to the first day of study treatment, C1D1Xx_NEWLINE_xXMajor surgery within 30 days prior or during the study periodXx_NEWLINE_xXMajor surgery within 14 days prior to start of study treatmentXx_NEWLINE_xXPatients must begin treatment as outlined in the protocol within 42 days of definitive surgery (day of surgery is day 0; definitive surgery includes last surgery to resect residual tumor)Xx_NEWLINE_xXPatients must begin treatment within 42 days of definitive surgery (day of surgery is day 0; definitive surgery includes repeat surgeries to resect residual tumor)Xx_NEWLINE_xXSubject has had major surgery within 21 days prior to the first dose of ABBV-399.Xx_NEWLINE_xXMust not have had major surgery or radiation therapy within 14 days of starting study treatmentXx_NEWLINE_xXMajor surgery (includes any surgery that carries significant risk of blood loss, extended periods of general anesthesia, or requires at least an overnight hospital admission) within 28 days before starting treatment or inadequately healed incision/scar from prior surgeryXx_NEWLINE_xXSubject has had major surgery within 28 days prior to study day 1Xx_NEWLINE_xXPrior surgery for this cancerXx_NEWLINE_xXPatient must be scheduled for elective major cancer surgery at Fox Chase Cancer Center (FCCC) =< 30 days after first registration\r\n* Elective surgery is defined as:\r\n** Patient is scheduled to be brought from their home (or normal living environment) to FCCC on the day of the index surgery AND\r\n** Surgery is not scheduled as urgent or emergentXx_NEWLINE_xXStatus post above elective surgery =< 30 days after first registration\r\n* Elective surgery is defined as:\r\n** Patient was brought from their home (or normal living environment) to FCCC on the day prior to surgery or the day of the index surgery AND\r\n** Surgery was not scheduled/performed as urgent or emergentXx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: Not able to receive the vaccination within 10 weeks following the surgery secondary to a delayed recovery from the surgeryXx_NEWLINE_xXMajor surgery within 21 days prior to randomisationXx_NEWLINE_xXFor subject’s who have received major surgery, the subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapyXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drugXx_NEWLINE_xXMajor surgery within 14 days before enrollment; the PI will serve as the final arbiter as to what constitutes major surgeryXx_NEWLINE_xXStable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections or major surgery within 28 days prior to study enrollmentXx_NEWLINE_xXWomen must not become pregnant prior to surgery or during the first 3 months after surgery; women who can become pregnant will be asked to practice an effective form of birth control for up to 3 months after surgeryXx_NEWLINE_xXPatients who have had previous thyroid surgeryXx_NEWLINE_xXMajor surgery requiring a prolonged hospitalization or recovery within 21 days before day 1 of study drugXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXHistory of rectal surgeryXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drug and have not recovered fully from any complications from surgery.Xx_NEWLINE_xXPatient has had major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these proceduresXx_NEWLINE_xXMajor surgery (e.g. thoracic, abdominal, vascular, neurosurgery) within 28 days prior to registration on the studyXx_NEWLINE_xXMajor surgery =< 14 days prior to registration or have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within 30 days prior to date of randomization.Xx_NEWLINE_xXMajor surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)Xx_NEWLINE_xXPatients must have recovered from the effects of surgery; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment; for core or needle biopsy, a minimum of 7 days must have elapsed prior to the day of protocol treatmentXx_NEWLINE_xXPatient is medically unfit for surgery or is deemed surgically unresectable by head and neck (H&N) surgeon within 60 days prior to enrollment, or patient refusal of surgeryXx_NEWLINE_xXPrevious thyroid surgeryXx_NEWLINE_xXBecomes pregnant before surgery or at any time while on studyXx_NEWLINE_xXSubjects having undergone recent resection or biopsy of an intracranial tumor will be eligible as long as all of the following conditions apply: \r\n* First dose of cabozantinib occurs at least 28 days after surgery, and the subject has recovered from the effects of surgeryXx_NEWLINE_xXPatients may not have had any prior tumor treatment except for surgery, and must have adequately recovered from surgeryXx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 21 daysXx_NEWLINE_xXMajor surgery within 21 days prior to enrollmentXx_NEWLINE_xXPatients who have undergone a major surgery, including surgery for a new artificial implant and/or device, within 6 weeks prior to the initiation of ADXS11-001 treatment; NOTE: All toxicities and/or complications must have recovered to baseline or grade\r\n1 prior to the initiation of ADXS11-001 study therapy; sponsor must be consulted prior to enrolling subjects on the study who recently had a major surgery or have new artificial implant, and/or devicesXx_NEWLINE_xXHave had major surgery within 21 days of starting therapy. Placement of a venous access device within 21 days of starting therapy is allowed.Xx_NEWLINE_xXPatients may have received prior surgery provided that at least 28 days have elapsed since major surgery (thoracic or other major surgeries) and the patient has recovered from all associated toxicities. Patients must have disease outside of the previous surgical resection area or a new lesion must be present.Xx_NEWLINE_xXMust have had no major surgery within 28 days prior to enrollment.Xx_NEWLINE_xXAny patient with surgery scheduled < 7 days after biopsyXx_NEWLINE_xXPatients who have had non-biopsy surgery in the last 10 daysXx_NEWLINE_xXMajor surgery within 21 days prior to first doseXx_NEWLINE_xXPatients with major surgery within 30 days prior to entering the studyXx_NEWLINE_xXHave undergone major surgery within 28 days prior to first dose of AP32788. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed.Xx_NEWLINE_xXMajor surgery =< 14 days before study registrationXx_NEWLINE_xXThe patient has undergone major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 2 days prior to first dose of protocol therapy; the patient has elective or planned major surgery to be performed during the course of the clinical trialXx_NEWLINE_xXMajor surgery as defined by the investigator within 2 weeks of the first dose of study treatment (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery)Xx_NEWLINE_xXPatients must not have any major surgery or radiation therapy within 14 days of start of study treatmentXx_NEWLINE_xXAll patients who have surgery performed must have a cranial MRI pre-operative and post-operative (should be done within 72 hours of surgery or within 21 days following surgery)Xx_NEWLINE_xXPatients must have recovered from the surgeryXx_NEWLINE_xXSurgery: Subjects who have received hepatic surgery, ablation or chemoembolization within 4 weeks of PV-10 administration.Xx_NEWLINE_xXMajor surgery within 30 days before the initiation of study treatmentXx_NEWLINE_xXMajor surgery (requiring general anesthesia) within 3 months prior to dosing.Xx_NEWLINE_xXCentral line placement or subcutaneous port placement is not considered major surgery but must be placed at least 2 days prior to study drug administrationXx_NEWLINE_xXMajor surgery =< 14 days prior to study registrationXx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 21 daysXx_NEWLINE_xXParticipant is able to undergo surgery (planned lobectomy or wedge resection)\r\n* Specifically, the participant has been or will have been cleared for surgery at the time of enrollment; the surgeon can accept the baseline tests done within 45 days prior to SBRT to clear the patient for surgeryXx_NEWLINE_xXMajor surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of immunotherapy; Note: Local surgery of isolated lesions for palliative intent is acceptableXx_NEWLINE_xXSubject has had major surgery within the last 28 daysXx_NEWLINE_xXMajor surgery within 14 days before the first dose of any study drug or a scheduled surgery during study periodXx_NEWLINE_xXMajor surgery within 14 days before enrollment.Xx_NEWLINE_xXMajor surgery (excluding placement of vascular access) ?21 days from beginning of the study drug or minor surgical procedures ?7 days. No waiting is required following implantable port and catheter placement.Xx_NEWLINE_xXMajor surgery within 30 days prior to enrollment.Xx_NEWLINE_xXPatients must be deemed to be in adequate health to undergo major surgery (pancreaticoduodenectomy)Xx_NEWLINE_xXinterval of ? 14 days between end of surgery and start of protocol therapy for patients who have undergone surgery for recurrent disease.Xx_NEWLINE_xXPatients who have undergone major surgery within 21 days prior to registration are NOT eligible for participationXx_NEWLINE_xXTime between primary surgery and randomization > 3 months.Xx_NEWLINE_xXRepeat surgery for recurrence of diseaseXx_NEWLINE_xXPatients who have had major surgery within the past 14 days.Xx_NEWLINE_xX214 Major surgery within 28 days of first dose AMG 562.Xx_NEWLINE_xXHas not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapyXx_NEWLINE_xXMajor surgery within 14 days prior to study entryXx_NEWLINE_xXMajor surgery 21 days or less prior to starting study drug or has not recovered from adverse effects from such procedure.Xx_NEWLINE_xXSystemic radiation therapy or major surgery < 28 days prior to study Day 1 as well as focal radiotherapy < 14 days prior to study Day 1.Xx_NEWLINE_xXMajor surgery within 14 days prior to start of study treatmentXx_NEWLINE_xXWho have had non-biopsy surgery in the last 10 daysXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Patients who have received major surgery must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Patients who have received major surgery must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients who have had major injuries and/or surgery within the past 4 weeks (< 28 days) prior to registration with incomplete wound healing and/or planned surgery while the patient is on study treatmentXx_NEWLINE_xXMajor surgery within 28 days prior to the first study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatmentXx_NEWLINE_xXMajor surgical procedure (as defined by the investigator) within 28 days prior to the first dose of investigational product (IP); Note: Local surgery of isolated lesions for palliative intent is acceptableXx_NEWLINE_xXMajor surgery (requiring general anesthesia) within 14 days before the first dose of study\r\ndrug or a scheduled surgery during study periodXx_NEWLINE_xXMajor surgery within 12 weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligibleXx_NEWLINE_xXPatients must have undergone surgery and must not have had any further treatment following surgery. Patients must have undergone surgery of their glioblastoma (GBM), and must not have had any further treatment following surgery. A minimal interval of 7 days between the day of surgery and the day of inclusion should be respected; a maximal interval of 31 days between the day of surgery and the day of inclusion should be respected; the patient should have fully clinically recovered from the surgery. (For stage 2: radiation with concurrent and adjuvant EDO-S101 only)Xx_NEWLINE_xXMajor surgery (as defined by the investigator) within the 28 days prior to day 1 of protocol therapyXx_NEWLINE_xXMajor operation within 14 days prior to starting study drug or not recovered from surgical complications; neither tumor biopsy nor central line insertion are considered a major operationXx_NEWLINE_xXMajor surgery within 28 days prior to first study treatment.Xx_NEWLINE_xXSurgery within 21 days prior to study entry.Xx_NEWLINE_xXMajor surgery within 28 days of C1D1Xx_NEWLINE_xXMajor thoracic or abdominal surgery from which the patient has not yet recovered.Xx_NEWLINE_xXSubjects who have undergone major surgery within 28 days of study day 1; vertebroplasty and/or kyphoplasty, which must have been performed at least 1 week prior to starting AMG-232 + KRdXx_NEWLINE_xXMajor surgery within 28 days of the first dose of study drugXx_NEWLINE_xXMajor surgery within 1 month prior to enrollment.Xx_NEWLINE_xXLumbar CSF must be obtained prior to study enrollment unless medically contraindicated; if a patient undergoes surgery and lumbar CSF cannot be obtained at this time, then it should be performed at least 10 days following surgery before study enrollment; false positive cytology can occur within 10 days of surgery; Note: patients with positive CSF cytology obtained prior to 10 days after surgery may have cytology repeated to determine eligibilityXx_NEWLINE_xXMajor surgery within 21 days of starting protocol treatmentXx_NEWLINE_xXParticipants who received major surgery must be recovered adequately from the toxicity and/or complications from the interventions prior to starting therapyXx_NEWLINE_xXPatients who have had major surgery or trauma within 28 days prior to entering the study; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatmentXx_NEWLINE_xXPatients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy; at least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay required for minor procedures (e.g., tumor fine-needle aspiration [FNA] or core biopsy, venous access device placement)Xx_NEWLINE_xXIbrutinib should be held at least 3 to 7 days pre- and post-surgery, depending upon the type of surgery and risk of bleedingXx_NEWLINE_xXRecent major surgery (within the past 14 days)Xx_NEWLINE_xXRecent resection of recurrent or progressive tumor allowed as long as at least 4 weeks have elapsed from date of surgery and the subject has recovered from surgeryXx_NEWLINE_xXNo prior radical prostate surgeryXx_NEWLINE_xXIbrutinib must be discontinued 7 days before (when possible) until 7 days after major surgery, and 3 days before (when possible) until 3 days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery > 7 days before initiating treatment, and/or must have completed minor surgery > 3 days before initiating treatmentXx_NEWLINE_xXMajor surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXMajor surgery =< 14 days prior to study registrationXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effectsXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXSubject has had major surgery within 14 days prior to starting study drug or has not recovered from major side effectsXx_NEWLINE_xXPrior significant rectal surgery (hemorrhoidectomy is acceptable)Xx_NEWLINE_xXSubjects must have recovered from surgery before study registrationXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXPatients who are not currently candidates for radical cystectomy (e.g. patient refuses surgery, comorbidities preclude major surgery, etc.)Xx_NEWLINE_xXPrior major surgery or radiation therapy within 14 days of initiation of treatmentXx_NEWLINE_xXNot likely curable with surgery aloneXx_NEWLINE_xXAt least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay in treatment for minor procedures (e.g., tumor core biopsy)Xx_NEWLINE_xXPatients who have undergone major surgery, excluding diagnostic biopsy, within 30 days (to allow for full recovery) prior to registrationXx_NEWLINE_xXPatients may have received prior surgery (e.g., pleurectomy, pleurodeisis) provided at least 28 days have elapsed since surgery (thoracic or other major surgeries) and patients have recovered from all associated toxicities at the time of registration; there must be no anticipated need for major surgical procedures during protocol treatmentXx_NEWLINE_xXPatients must not have had major surgery within 28 days prior to registration or be scheduled for surgery during the projected course of protocol treatment; tumor biopsy is allowedXx_NEWLINE_xXPatients must have recovered from prior surgery based on treating physician's discretionXx_NEWLINE_xXPatients may have received prior surgery; for all major surgeries, at least 14 days must have elapsed since completion and patient must have recovered from all major side effects of surgery per investigator’s assessmentXx_NEWLINE_xXMajor surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgeryXx_NEWLINE_xXThe participant underwent major surgery within 28 days.Xx_NEWLINE_xXMajor surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgeryXx_NEWLINE_xXNo major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomizationXx_NEWLINE_xXNot curable by surgery.Xx_NEWLINE_xXThe patient has undergone major surgery within 28 days prior to first dose of protocol therapyXx_NEWLINE_xXPatients who have elective or planned major surgery to be performed during the course of the clinical trial; minor surgery/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy is permittedXx_NEWLINE_xXhad major surgery within 14 days prior to randomizationXx_NEWLINE_xXAvastin use within 30 days prior to surgery.Xx_NEWLINE_xXSubject is scheduled for another surgery during the first 6 months following surgery (not including stoma closure ,placement of port for chemotherapy or ureter stent insertion).Xx_NEWLINE_xXPRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within 28 days prior to registration; patients must have recovered from any adverse effects of prior surgery to the satisfaction of the treating physician; biopsies and central IV access placement are not considered major surgeryXx_NEWLINE_xXHave undergone major surgery within 28 days (?28 days) prior to randomization or subcutaneous venous access device placement within 7 days (?7 days) prior to randomization.Xx_NEWLINE_xXMajor surgery within 21 days of starting protocol treatmentXx_NEWLINE_xXSubject has had major surgery within 14 days prior to starting study drug or has not recovered from major side effectsXx_NEWLINE_xXMajor surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)Xx_NEWLINE_xXMajor surgery within 28 days prior to randomizationXx_NEWLINE_xXAt least 4 weeks must have elapsed since the patient underwent any major surgery (eg. MAJOR: laparotomy, laparoscopy, thoracotomy, VATS [video assisted thorascopic surgery]); there is no restriction on MINOR procedures: (eg. central venous catheter placement, ureteral stent placement or exchange, tumor core or fine-needle aspirate [FNA] biopsy)Xx_NEWLINE_xXAt least 7 days since any minor surgery such as port placementXx_NEWLINE_xXIf a second surgery is needed for completion of resection, this should be within 30 days from the first surgeryXx_NEWLINE_xXSurgery must have confirmed the recurrenceXx_NEWLINE_xXHistory of any major rectal or pelvic surgery or radiotherapyXx_NEWLINE_xXSubject has received prior therapy for cancer or major surgery within 28 days, or 42 days for nitrosourea or mitomycin C, prior to Cycle 1 Day 1, or 14 days for tamoxifen;Xx_NEWLINE_xXMajor surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatmentXx_NEWLINE_xXScheduled for major surgery during the study.Xx_NEWLINE_xXMajor surgery within 28 days before randomizationXx_NEWLINE_xXMajor surgery within 28 days prior to first dose of study drugXx_NEWLINE_xXHave had major surgery within 7 days prior to initiation of study drug to allow for postoperative healing of the surgical wound and site(s).Xx_NEWLINE_xXPrior chemotherapy, radiotherapy, biological cancer therapy or major surgery within 28 days prior to enrollmentXx_NEWLINE_xXPatient has had major surgery =< 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXPatients who have had major surgery within one month (28 days) prior to registration are not eligibleXx_NEWLINE_xXMajor surgery within 28 days before randomisation.Xx_NEWLINE_xXHas had major surgery within 3 weeks prior to enrollment (a percutaneous biopsy, pleural catheter insertion, placement of central venous catheter or other minor procedure are permitted)Xx_NEWLINE_xXHad major surgery within 30 days of the first dose of study drug, minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.Xx_NEWLINE_xXSUB-PROTOCOL AIM A: Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) =< 4 weeks prior to registration or failure to recover from side effects of such surgery; exceptions: port placements, nephrectomy, tumor biopsies, and minor surgeriesXx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 21 daysXx_NEWLINE_xXSurgery completed at least 28 days before randomization;Xx_NEWLINE_xXExpected to have surgery during study period;Xx_NEWLINE_xXHave an elective or a planned major surgery during the course of the trial or has undergone major surgery within 28 days prior to enrollment.Xx_NEWLINE_xXMajor surgery within 28 days (four weeks) prior to registration.Xx_NEWLINE_xXNo major surgery within 28 days prior to treatment; no minor surgery within 5 days prior to treatmentXx_NEWLINE_xXNo history of major surgery =< 14 days prior to registrationXx_NEWLINE_xXSubject has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to day 1 of treatment in this studyXx_NEWLINE_xXMajor surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube) within 28 days of C1D1Xx_NEWLINE_xXPatients who have undergone major surgery within 14 daysXx_NEWLINE_xXMajor surgery, within 28 days of first dose of study drugXx_NEWLINE_xXMajor surgery within 30 days prior to enrollment.Xx_NEWLINE_xXMajor surgery within 14 days before first dose or a scheduled surgery during study period; insertion of a venous access device (eg, catheter, port) is not considered major surgery.Xx_NEWLINE_xXKnown need for major surgery within 14 days of the first dose of Ribociclib. Gastrostomy, insertion of a G tube, Ventriculo-peritoneal shunt, endoscopic ventriculostomy and central venous access are NOT considered major surgery.Xx_NEWLINE_xXMajor surgery performed < 28 days from treatment startXx_NEWLINE_xXMajor surgery within 28 days of study drugXx_NEWLINE_xXHave had major surgery (excluding biopsy) < 28 days of the initial dose of study drug.Xx_NEWLINE_xXAre scheduled for debulking surgery during the studyXx_NEWLINE_xXSubject has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to day 1 of treatment in this studyXx_NEWLINE_xXHave undergone major surgery within 28 days prior to randomization, or central venous access device placement within 7 days prior to first dose of study treatment, except if the procedure is minimally invasive (for example, introduction of peripherally inserted central catheter [PICC] line) and the investigator does not anticipate any significant bleeding.Xx_NEWLINE_xXHas had major surgery within 21 days before cycle 1 day 1Xx_NEWLINE_xXHave had major surgery within 14 days prior to randomizationXx_NEWLINE_xXAt least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: hysterectomy, resection of a lung nodule; minor: central venous access catheter placement).Xx_NEWLINE_xXPatients with a history of prior pituitary surgery must be at least 30 days post-surgery to be eligible for inclusion in this study.Xx_NEWLINE_xXPatients who have undergone major surgery within 1 month prior to screening.Xx_NEWLINE_xXPatient must be eligible for abdominal surgeryXx_NEWLINE_xXUndergone major surgery within 28 days prior to first dose of study drug or have subcutaneous venous access device placement within 7 days prior to first dose. Additional Exclusion Criteria For Part DXx_NEWLINE_xXMajor surgery within 14 days before first dose of study drugXx_NEWLINE_xXMajor surgery within six weeks or open biopsy within 14 days before drug infusion.Xx_NEWLINE_xXPlan for any major surgery during treatment period.Xx_NEWLINE_xXPatients may not have had major surgery within 10 days of enrollment, or minor surgery within 7 days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physicianXx_NEWLINE_xXAny surgery, where general anesthesia was administered, must have occurred at least 7 days prior to study enrollmentXx_NEWLINE_xXPatients must not have had major surgery within 6 weeks prior to enrollment on the high risk stratum; patients with history of recent minor surgical procedures (vascular catheter placement, bone marrow evaluation, laparoscopic surgery, liver tumor biopsy) will be eligibleXx_NEWLINE_xXMajor surgery within 28 days of study day 1Xx_NEWLINE_xXSystemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within 21 days of the first dose of trial medicationXx_NEWLINE_xXMajor surgery within 28 days before Cycle 1 Day 1Xx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered a major surgery)Xx_NEWLINE_xXAny major surgery =< 28 days prior to the initiation of investigational productsXx_NEWLINE_xXMajor surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary)Xx_NEWLINE_xXMajor surgery within 28 days before the start of trial treatment (prior diagnostic biopsy is permitted)Xx_NEWLINE_xXAdequate recovery from all recent surgery is required; at least 1 week must have elapsed from the time of a minor surgery; at least 21 days must have elapsed from the time of a major surgery. Patients must have recovered from all surgery-related toxicities to Grade 1 or less.Xx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery).Xx_NEWLINE_xXPregnant at time of surgeryXx_NEWLINE_xXMajor surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery (excluding tumor biopsies) within 14 days of first dose of study treatmentXx_NEWLINE_xXSubjects enrolling on the ibrutinib arm must not have had major surgery within 14 days, or minor surgery within 7 daysXx_NEWLINE_xXSubject undergoing cardiothoracic surgery is not allergic to protamine; andXx_NEWLINE_xXSubject receiving intravenous heparin within 12 hours before surgery or oral Coumadin within 2 days before surgery;Xx_NEWLINE_xXSubject receiving antiplatelet medications within 5 days prior to surgery;Xx_NEWLINE_xXSubject undergoing abdominal or orthopedic lower extremity surgery receiving aspirin within 7 days prior to surgery;Xx_NEWLINE_xXHave had major surgery within 14 days prior to randomization of study drug to allow for post-operative healing of the surgical wound and site(s).Xx_NEWLINE_xXIf patients underwent surgery, and chemotherapy is indicated after surgery either as adjuvant or to treat residual disease, study treatment should be initiated within 8 weeks of surgeryXx_NEWLINE_xXIf subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMajor surgery within 14 days prior to enrollmentXx_NEWLINE_xXPatients may have received prior surgery (e.g., pleurectomy) provided that at least 28 days have elapsed since surgery (thoracic or other major surgeries) and patients have recovered (i.e., =< grade 1 or at baseline) from all associated toxicities at the time of registration; there must be no anticipated need for major surgical procedures during protocol treatmentXx_NEWLINE_xXNo major injuries within the past 10 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study periodXx_NEWLINE_xXMajor surgical procedure, as defined by the investigator, within 28 days prior to the first dose of IP; Note: local surgery or isolated lesions for palliative intent is acceptableXx_NEWLINE_xXPatients who have undergone major surgery within 7 days or minor surgery within 3 days of first dose of study drugXx_NEWLINE_xXMajor surgery within 30 days before study entry.Xx_NEWLINE_xXThe participant has undergone major surgery or received anti-cancer monoclonal antibody therapy in the 30-days prior to study enrollment.Xx_NEWLINE_xXThe participant underwent major surgery within 28 days prior to randomization or central venous access device placement within 7 days prior to randomization.Xx_NEWLINE_xXIf subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXMajor surgery (such as GI surgery) within 6 weeks of enrollment; however, subjects who have had a nephrectomy may be enrolled 4 weeks after surgery, providing there are no wound-healing complications; subjects with clinically relevant ongoing complications from prior surgery are not eligible; the following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental proceduresXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXHas had major surgery or significant traumatic injury within 4 weeks of study registration. Subjects must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. A diagnostic or research biopsy does not exclude subjects from enrollment. Placement of a vascular access device such as a Port-A-Cath is not considered major surgeryXx_NEWLINE_xXMajor surgery within 30 days prior to start of study drugXx_NEWLINE_xXSurgery within 4 weeks prior to study treatment except for minor procedures: NOTES: Hepatic biliary stent placement is allowed. Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.Xx_NEWLINE_xXMajor surgery within 14 days prior to start of treatment; no time limitations after minor surgery (e.g.: core biopsy or central line placement)Xx_NEWLINE_xXPatients must be recovered from effects of recent surgery (28 days must elapse between surgery and the start of treatment with cabozantinib)Xx_NEWLINE_xXPatients may not have had major surgery or radiotherapy (therapeutic and/or palliative) within 14 days prior to initiation of study treatment, including CNS-directed radiation therapy; minor procedures, such as tumor biopsy, thoracentesis, or intravenous catheter placement are allowed with no waiting periodXx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 21 daysXx_NEWLINE_xXAny minor surgery or core biopsy completed >= 1 week prior to randomization and patient must have fully recovered from the procedure; Note: insertion of a vascular access device is not considered major or minor surgeryXx_NEWLINE_xXAny major surgery or extensive radiotherapy within 28 days prior to screeningXx_NEWLINE_xXMajor surgery or radiation therapy within 30 days of screening visitXx_NEWLINE_xXPrior systemic chemotherapy, radiation therapy or major surgery =< 30 days prior to registrationXx_NEWLINE_xXPatients with recent major surgery within 14 days prior to cycle 1, day 1Xx_NEWLINE_xXAt least 3 months have elapsed between any prior brain radiotherapy and initiation of study therapy (unless the subject recently underwent surgery for proven or suspected disease recurrence, the histology of the most recent surgery demonstrated recurrent/progressive/persistent malignant glioma, Gliadel wafers were not placed during the most recent surgery, neither convection enhanced delivery nor catheters for infusion of chemotherapy were use during the most recent surgery, and radioactive seeds were not placed during the most recent surgery)Xx_NEWLINE_xXMajor surgery (as defined by the investigator) within 4 weeks prior to first dose of MEDI6383 or still recovering from prior surgery. Local surgery of isolated lesions for palliative intent is acceptableXx_NEWLINE_xXPatients who have had major surgery within 28 days prior to entry into the study or be recovering from any effects of surgery; patients who have had minor surgery within 2 weeks prior to entry into the studyXx_NEWLINE_xXNo defined washout period from major or minor surgery is required but incisions must be fully healedXx_NEWLINE_xXMajor surgery within 30 days prior to start of study drugXx_NEWLINE_xXMajor surgery within 14 days before randomization.Xx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 21 daysXx_NEWLINE_xXMajor surgery or radiotherapy within 14 days of randomization.Xx_NEWLINE_xXMajor surgery =< 28 days prior to registrationXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXHave had major surgery within 14 days prior to randomization of study drug to allow for post-operative healing of the surgical wound and site(s)Xx_NEWLINE_xXMajor surgery within 21 days prior to the first day of treatmentXx_NEWLINE_xXMajor surgery within 28 days prior to the first dose of study medicationXx_NEWLINE_xXHas had major surgery within 28 days prior to enrollmentXx_NEWLINE_xXNo major surgery within the last 4 weeks (28 days) of first dose of study drug or minor surgery within 3 days of first dose of study drugXx_NEWLINE_xXIf most recent therapy was surgery, participants must be at least 30 days out from definitive surgery with no active wound healing complicationsXx_NEWLINE_xXHistory of major/minor surgery as follows:\r\n* Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n* Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications; in addition complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryXx_NEWLINE_xXMajor thoracic or abdominal surgery from which the patient has not yet recovered.Xx_NEWLINE_xXNo major surgery within 14 days and minor surgery within 7 days prior to cycle 1 day 1Xx_NEWLINE_xXMajor surgery within the 28 days preceding the first dose of study drugXx_NEWLINE_xXSurgery: >= 3 weeks from major surgery; if recent craniotomy, adequate wound healing must be determined by neurosurgical teamXx_NEWLINE_xXMajor surgery (includes surgery that carries significant risk of blood loss, extended periods of general anesthesia, or requires at least an overnight hospital admission) within 28 days before starting treatmentXx_NEWLINE_xXMajor surgery within 30 days prior to the first dose of study treatmentXx_NEWLINE_xXPrevious laryngeal surgeryXx_NEWLINE_xXThe patient has had minor surgery ? 7 days from the start of study treatment (excluding the placement of central/peripheral lines, skin biopsy).Xx_NEWLINE_xXMajor surgery or trauma within 28 days prior to first dose of study treatment and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)Xx_NEWLINE_xXPrior major surgery less than 14 days prior to enrollment. Any surgery-related AE(s) must have resolved prior to enrollmentXx_NEWLINE_xXMargin negative surgeryXx_NEWLINE_xXMajor surgery within 1 month prior to enrollment.Xx_NEWLINE_xXIf the patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas undergone major surgery and has not recovered adequately from any toxicity and/or complications from the intervention prior to starting study therapyXx_NEWLINE_xXParticipants who have had any major surgery =< 28 days prior to the planned initiation of study therapy, or those who have not recovered from adverse events due to agents/surgery administered more than 4 weeks earlierXx_NEWLINE_xXMajor surgery within 21 days prior to signing consentXx_NEWLINE_xXSurgery or local prostatic intervention within 30 days of the first dose; in addition, any clinically relevant issues from the surgery must have resolved prior to enrollmentXx_NEWLINE_xXPART B: Patients who have had major surgery within 28 days prior to entering the study or those who have not recovered from adverse events > grade 1 relating to the surgeryXx_NEWLINE_xXPatients may have received prior surgery (for both the primary and stage IV disease); all adverse events associated with prior surgery must have resolved to =< grade 1 prior to registrationXx_NEWLINE_xXREGISTRATION TO SURGERY (ARM S)Xx_NEWLINE_xXPatients must register to Step 1 prior to surgeryXx_NEWLINE_xXPatients with recent resection for recurrent disease must have recovered from the effects of surgery and should not start treatment for at least 28 days after surgeryXx_NEWLINE_xXPatients may have received prior surgery; however, at least 21 days must have elapsed since completion of surgery and the patient must have recovered from all side effectsXx_NEWLINE_xXScheduled for surgery during the study.Xx_NEWLINE_xXMajor surgery or radiotherapy within 14 days before randomizationXx_NEWLINE_xXMajor surgery within 30 days prior to start of study drugXx_NEWLINE_xXPatients should have completed any major surgery >= 4 weeks prior to registration and must have completed any minor surgery >= 2 weeks prior to registration; patients must have fully recovered from the procedure\r\n* The following are examples of procedures considered to be minor: port placement, laparoscopy, thoracoscopy, bronchoscopy, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and dental extraction procedures\r\n* Insertion of a vascular access device, thoracentesis, paracentesis, and endoscopic ultrasonographic procedures are not considered to be major or minor surgeriesXx_NEWLINE_xXMajor surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)Xx_NEWLINE_xXPatients who have had major surgery or radiation therapy within 21 days of starting treatmentXx_NEWLINE_xXMinor surgery < 2 weeks from the start of treatment; (insertion of a vascular access device is not considered major or minor surgery)Xx_NEWLINE_xXPatients who have had any major surgery within 21 days prior to enrollmentXx_NEWLINE_xXAny major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ? 2 weeks);Xx_NEWLINE_xXPatients may have received Gliadel during surgeryXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drugXx_NEWLINE_xXPatients who have not recovered from prior surgeryXx_NEWLINE_xXIncomplete healing from previous oncologic or other major surgeryXx_NEWLINE_xXPatients with major surgery within 28 days prior to treatmentXx_NEWLINE_xXA candidate for curative surgeryXx_NEWLINE_xXRecent major surgery within the prior 4 weeks; (mediastinoscopy or placement of a central venous access will be allowed as long as placement was more than 7 days prior to receiving study drug)Xx_NEWLINE_xXMajor surgery within 28 days prior to enrollment or still recovering from prior surgeryXx_NEWLINE_xXPatients that may require major surgery during the course of the studyXx_NEWLINE_xXPatients expected to get surgery.Xx_NEWLINE_xXMajor surgery within 4 weeks before day 1 (this does not include placement of vascular access device or tumor biopsies)Xx_NEWLINE_xXPatients with major surgery within 30 days prior to entering the studyXx_NEWLINE_xXMajor surgery within 14 days before randomization.Xx_NEWLINE_xXPatients must be a candidate for surgeryXx_NEWLINE_xXPatients should have completed any major surgery or open biopsy >= 4 weeks from start date of chemotherapy; patients must have completed any minor surgery or core biopsy >= 1 week prior to first dose of bevacizumab; (insertion of a vascular access device is not considered major or minor surgery)Xx_NEWLINE_xXPrior treatment (major surgery, radiation therapy, chemotherapy, or other investigational drugs) received within 28 days before randomization.Xx_NEWLINE_xXMajor surgery (excluding lymph node biopsy) within 28 days prior to signing informed consent.Xx_NEWLINE_xXHistory of gastrointestinal (GI) surgery within the past 28 days; if > 28 days since GI surgery, must have confirmation of complete healing before initiating treatment with study drugXx_NEWLINE_xXMajor surgery within 28 days of Day 1Xx_NEWLINE_xXMajor surgery within 14 days before study registrationXx_NEWLINE_xXMajor surgery within 28 days prior to registrationXx_NEWLINE_xXMajor surgery within 14 days and minor surgery within 7 days prior to cycle 1 day 1Xx_NEWLINE_xXAppropriate candidate for surgeryXx_NEWLINE_xXMajor surgical procedure or any radiation therapy within 4 weeks of treatment, minimum rest period is 28 days post surgery; maximum rest period 56 days post surgeryXx_NEWLINE_xXPatients who have undergone major surgery within 4 weeks prior to study enrollment (tracheotomy, feeding tube or vascular access catheter placement and interventional procedures such as bronchoscopy, upper gastrointestinal [GI] endoscopy or colonoscopy are not considered major surgery)Xx_NEWLINE_xXPatient has undergone a major surgery, including surgery for a new artificial implant and/or device, within 6 weeks prior to the initiation of ADXS11-001 treatment; NOTE: all toxicities and/or complications must have recovered to baseline or grade 1 prior to the initiation of ADXS11-001 study therapy; sponsor must be consulted prior to enrolling patients on the study who recently had a major surgery or have new artificial implant, and/or devicesXx_NEWLINE_xXThe participant has undergone major surgery within 28 days prior to randomization or has undergone central venous access device placement within 7 days prior to randomizationXx_NEWLINE_xXUnderwent major surgery within 14 days prior to first dose of ponatinibXx_NEWLINE_xXPatients with major surgery within 30 days prior to entering the studyXx_NEWLINE_xXIncomplete healing from previous oncologic or other major surgeryXx_NEWLINE_xXPatients who have undergone major surgery (including open biopsy, thoracotomy, organ resection, exploratory laparotomy, arteriovenous grafts) < 28 days prior to enrollment will have bevacizumab dosing delayedXx_NEWLINE_xXPatients with prior abdominal surgery within 30 days prior to entering the studyXx_NEWLINE_xXPrior major surgery (defined as requiring general anesthesia) or trauma within 28 days prior to first dose of study drug, and/or not recovered from effects of that surgery, and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major), or patients that may require surgery during the course of the studyXx_NEWLINE_xXEXPANSION COHORT ONLY: Prior major surgery (defined as requiring general anesthesia) or trauma within 28 days prior to first dose of study drug, and/or not recovered from effects of that surgery, and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major), or patients that may require surgery during the course of the studyXx_NEWLINE_xXNo major surgery within 30 days prior to registration for protocol therapy. Placement of a venous access device within 30 days prior to registration for protocol therapy is allowed.Xx_NEWLINE_xXSubject has had at least 4 weeks of postoperative recovery from surgery prior to enrollment to ensure complete wound healing; subjects with bowel resections at surgery who enroll in cohort 3 will begin protocol at least 42 days after surgery if debulking surgery had comprised of bowel resection or other bowel surgeryXx_NEWLINE_xXMajor surgery within 7 days of enrollmentXx_NEWLINE_xXMajor surgery within 28 days of starting study treatment; there is no minimum time requirement for minor procedures such as biopsy or vascular access placementXx_NEWLINE_xXMajor surgery within three months prior to Day 1 of study or who have not recovered adequately from prior surgery.Xx_NEWLINE_xXAny major surgery or extensive radiotherapy within 21 days of starting treatment on protocolXx_NEWLINE_xXAt least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay in treatment for minor procedures (e.g., central venous access catheter placement)Xx_NEWLINE_xXMajor surgery (e.g., requiring general anesthesia) within 3 weeks before screening, or has not fully recovered from prior surgery (i.e., unhealed wound), or surgery planned during the time the patient is expected to participate in the study. Note: patients with planned surgical procedures to be conducted under local anesthesia may participate.Xx_NEWLINE_xXMajor surgery within 14 days prior to the first dose of study drugXx_NEWLINE_xXMajor or minor surgery < 28 and <14 days from the start of treatment, respectively;Xx_NEWLINE_xXHistory of surgery within last 28 daysXx_NEWLINE_xXPatients with or with anticipation of invasive procedures as defined below: Major surgical procedure within 28 days of initiating bevacizumab or major procedures anticipated during the course of the study. This includes, but is not limited to abdominal surgery (laparotomy or laparoscopy) prior to disease progression, such as colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or second look surgery.Xx_NEWLINE_xXMajor surgery or trauma occurring within 28 days of starting the trialXx_NEWLINE_xXPrior therapy for melanoma except surgeryXx_NEWLINE_xXPatient must be suitable candidates for surgery.Xx_NEWLINE_xXPatients with contraindications to surgery;Xx_NEWLINE_xXMajor surgery within 28 daysXx_NEWLINE_xXMajor surgery within 30 days of study medicationXx_NEWLINE_xXMajor surgery within 21 days prior to the first dose of ABBV-838Xx_NEWLINE_xXMajor surgery within 28 days of the first dose of study treatmentXx_NEWLINE_xXHas had major surgery (requiring at least a 3 day hospital stay) in the past 28 daysXx_NEWLINE_xXMajor surgery of the spine in same region as the index vertebra(e) was performed within 3 months before enrollment,Xx_NEWLINE_xXMajor surgery within 28 days prior to the first dose of study drug.Xx_NEWLINE_xXUndergone major surgery within 30 days prior to randomizationXx_NEWLINE_xXHas had major surgery requiring general anesthesia and/or mechanical ventilation within the 28 days prior to randomizationXx_NEWLINE_xX28 days for cytotoxic chemotherapy, immunotherapy, whole brain radiotherapy, anticonvulsive therapy, stereotactic radiosurgery and major surgeryXx_NEWLINE_xXMajor surgery within 4 weeks (less than 28 days) prior to C1D1Xx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXMajor surgery within 28 days of study day 1Xx_NEWLINE_xXMajor injuries within the past 10 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study periodXx_NEWLINE_xXMajor surgery within 28 days prior to the first dose of study drug.Xx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXAdequate recovery from recent surgery; at least one week must have elapsed from minor surgery (placement of venous access device or fine needle aspiration) and at least 4 weeks from major surgeryXx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXPatients may not begin protocol therapy within 7 days of major surgery or within 3 days of minor surgeryXx_NEWLINE_xXMajor surgery within 28 days of first dose of study drugXx_NEWLINE_xXAny surgical procedure, excluding central venous catheter placement, bone marrow biopsy, lumbar puncture, or other minor procedures (e.g., skin biopsy) within 14 days of day 1; patients who have undergone major surgery =< 21 days prior to starting study drug or who have not recovered from side effects of such procedure are ineligible for the studyXx_NEWLINE_xXRecent resection of recurrent or progressive tumor allowed as long as at least 4 weeks have elapsed from date of surgery & subject has recovered from surgeryXx_NEWLINE_xXPrior to study treatment administration, at least 21 days must have elapsed since the subject's prior investigational or non-investigational systemic therapy, or any major surgery, and at least 21 days since prior radiotherapy.Xx_NEWLINE_xXSubject has received any chemotherapy, immunotherapy, vaccines, monoclonal antibodies, whether conventional or investigational, major surgery within 21 days, or radiotherapy within 21 days of treatment in this study, or at any time during the study.Xx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXMajor surgery requiring general anesthesia within 21 days or minor surgery within 14 days of study enrollment; subjects must have recovered from surgery related toxicitiesXx_NEWLINE_xXPrior pancreatic surgeryXx_NEWLINE_xX9. Major surgery within 28 days prior to the first dose of study drug.Xx_NEWLINE_xXMajor surgery (with the exception of minor surgical procedures, such as catheter placement or tumor biopsy) within 28 days prior to the first dose of ponatinibXx_NEWLINE_xXREGISTRATION #2: SURGERYXx_NEWLINE_xXAny prior surgery at the proposed treatment site OR any prior surgery involving the cryoablation-treated tumorXx_NEWLINE_xXSURGERY:Xx_NEWLINE_xXinterval of at least 3 weeks between end of surgery for recurrent disease and start of protocol therapy for patients who have undergone surgery for recurrent diseaseXx_NEWLINE_xXHistory of weight loss surgeryXx_NEWLINE_xXPatient with major surgery or radiotherapy within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1). Prior surgery or radiation therapy aimed at local palliation or attempted local disease control is permittedXx_NEWLINE_xXMajor surgery within 28 daysXx_NEWLINE_xXPatient had major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgeryXx_NEWLINE_xXMajor surgery within 1 month prior to enrollmentXx_NEWLINE_xXScheduled for major surgery during the study.Xx_NEWLINE_xXOther clinically significant disorders such as:\r\n* Severe active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and Mediport placement\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryXx_NEWLINE_xXIncomplete healing from previous oncologic treatments or other major surgeryXx_NEWLINE_xXAny major surgery =< 28 days prior to registrationXx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.Xx_NEWLINE_xXHave undergone major surgery within 28 days prior to receiving study drugs.Xx_NEWLINE_xXSubject has history of major surgery as follows:\r\n* Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n* Minor surgery within 1 months of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n* In addition complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryXx_NEWLINE_xXMajor surgery within 14 days before day 1.Xx_NEWLINE_xXTreatment with surgery or chemotherapy within 21 days prior to study entryXx_NEWLINE_xXSignificant traumatic injury or major surgery (major surgery means opening of a body cavity, eg, thoracotomy, laparotomy, laparoscopic organ resection, and major orthopedic procedures, eg, joint replacement, open reduction and internal fixation) within 21 days of scheduled dosing day 1;Xx_NEWLINE_xXIf a subject received major surgery, must have recovered adequately from the toxicity and/or complications from the intervention prior to enrollment.Xx_NEWLINE_xXMajor surgery, chemotherapy, investigational agent, or radiation within 30 days of DayXx_NEWLINE_xXMajor surgery within 28 days before Cycle 1 Day 1Xx_NEWLINE_xXCardiogenic shock at the time of surgery.Xx_NEWLINE_xXTreatment with Clopidogrel and Ticagrelor within 5 days before surgery, Prasugrel within 7 days before surgery, glycoprotein IIb/IIIa receptor blockers within 24 hours of surgery.Xx_NEWLINE_xXMajor surgery within 28 days of study day 1Xx_NEWLINE_xXsurgery, radiation, or immunosuppressants within 28 daysXx_NEWLINE_xXPatients scheduled to have routine surgery during the study duration.Xx_NEWLINE_xXMajor surgery within six weeks or open biopsy within 14 days before drug infusion.Xx_NEWLINE_xXPlan for any major surgery during treatment period.Xx_NEWLINE_xXAfter definitive surgery, e.g.Xx_NEWLINE_xXMajor surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (ie, larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy) within 28 days of first dose of study drugXx_NEWLINE_xXMajor surgery within 14 days prior to starting Investigational Product or has not recovered from major side effects.Xx_NEWLINE_xXAny major surgery (e.g. requiring general anesthesia).Xx_NEWLINE_xXMajor surgery ? 21 days from beginning of study drugXx_NEWLINE_xXIbrutinib must be discontinued 7 days before (when possible) until 7 days after major surgery, and 3 days before (when possible) until 3 days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery within 4 weeks before initiating treatment, and/or must have completed minor surgery > 3 days before initiating treatmentXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drug.Xx_NEWLINE_xXPrior major surgery from which the subject has not yet recovered to baseline;Xx_NEWLINE_xX14 days must have elapsed since prior major surgeryXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study treatment.Xx_NEWLINE_xXLess than 28 days elapsed from prior radiotherapy, from prior surgery and prior chemotherapy to the time of randomization; less than 42 days elapsed from prior major surgery to the time of randomizationXx_NEWLINE_xXPatients who have had major surgery within 14 days of study enrollmentXx_NEWLINE_xXMajor surgery within 28 days before the first dose of study drugXx_NEWLINE_xXMajor surgery within 30 days prior to date of randomization.Xx_NEWLINE_xXMajor surgery within 21 days before Study Day 1;Xx_NEWLINE_xXRecent major surgery or trauma, unhealing/open wounds.Xx_NEWLINE_xXAny major surgery or extensive radiotherapy within 21 days prior to randomization and crossoverXx_NEWLINE_xXMajor surgery (excluding kyphoplasty) within 28 days prior to randomizationXx_NEWLINE_xXMajor surgery, chemotherapy, investigational agent, or radiation within 30 days of Day 1Xx_NEWLINE_xXPrior major surgery or trauma within 28 days before first dose of study drugXx_NEWLINE_xXHistory of major surgery as follows:\r\n* Major surgery within 3 months of the first dose of cabozantinib; major surgery within 6 months of the first dose of cabozantinib if there are complications related to wound healing\r\n* Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications (particularly when associated with delayed or incomplete healing) within 28 days; Note: complete healing following abdominal surgery must be confirmed prior to initiating treatment with cabozantinib even if surgery occurred more than 28 days agoXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drugXx_NEWLINE_xXMajor surgery or radiotherapy within 14 days before study drug administrationXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drugXx_NEWLINE_xXMajor surgery within 21 days prior to first doseXx_NEWLINE_xXMinimum of 21 days have elapsed since prior major surgery, with recovery from any adverse events.Xx_NEWLINE_xXMajor surgery within 21 days prior to randomizationXx_NEWLINE_xXAll known lesions were previously treated with surgery or stereotactic surgery (whole-brain radiation is not allowed unless given after definitive treatment with surgery or stereotactic surgery) ANDXx_NEWLINE_xXThe subject had had major surgery within 28 days prior to the first dose of ABT-414.Xx_NEWLINE_xXMajor surgery within 30 daysXx_NEWLINE_xXMajor surgery =< 14 days prior to registrationXx_NEWLINE_xXMajor surgery within 21 days prior to first doseXx_NEWLINE_xXPrevious major surgery within 28 days prior to enrolmentXx_NEWLINE_xXGI surgery (particularly when associated with delayed or incomplete healing) within 28 days; Note: complete healing following abdominal surgery must be confirmed prior to initiating treatment with cabozantinib even if surgery occurred more than 28 days agoXx_NEWLINE_xXOther clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* Major surgery (eg, thoracotomy, removal or biopsy of brain metastasis) within 3 months before week 1 day 1; complete wound healing from major surgery must have occurred 1 month before week 1 day 1 and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before week 1 day 1; subjects with clinically relevant ongoing complications from prior surgery are not eligibleXx_NEWLINE_xXPatients must have recovered from the effects of surgery and a minimum of 14 days must have elapsed from the day of surgery to the day of registration; for core or needle biopsy, a minimum of 7 days must have elapsed prior to registrationXx_NEWLINE_xXBe candidates for clinical resection but for whom surgery is not urgently indicated (eg, for whom surgery within the next 2-4 months is appropriate).Xx_NEWLINE_xXMajor surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgeryXx_NEWLINE_xXMajor surgery (excluding kyphoplasty) within 28 days prior to randomization.Xx_NEWLINE_xXMajor surgery within 28 days prior to enrollment or still recovering from prior surgeryXx_NEWLINE_xXPatients with major surgery within 30 days prior to entering the studyXx_NEWLINE_xXMajor surgery or radiotherapy within 14 days before the first dose of study drugXx_NEWLINE_xXHas major surgery or radiotherapy within 14 days before the first dose of study drugXx_NEWLINE_xXMajor surgery within 21 days prior to randomization.Xx_NEWLINE_xXSubjects who received any of the following within the last 14 days of initiation of study treatment: 1) Plasmapheresis, 2) Major surgery, 3) Radiation therapy, 4) Use of any anti-myeloma drug therapyXx_NEWLINE_xXMajor surgery within 30 days of study day 1Xx_NEWLINE_xXMajor surgery within 14 days of initiation of study drug treatmentXx_NEWLINE_xXMajor surgery with incompletely healed surgical incision before starting study therapyXx_NEWLINE_xXHas undergone major surgery within 4 weeks prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomizationXx_NEWLINE_xXThe participant has undergone major surgery within 28 days prior to randomization.Xx_NEWLINE_xXMajor surgery within 28 days prior the first dose of study medication, or subcutaneous venous access device placement within 7 days prior to randomizationXx_NEWLINE_xXMajor surgery within 21 days prior to randomizationXx_NEWLINE_xXSurgery within 28 days prior to randomizationXx_NEWLINE_xXThe subject has had prior major surgery within 30 days prior to first dose of study drugXx_NEWLINE_xXNo major surgery within 28 days of study entryXx_NEWLINE_xXCardiac valvular surgery or open heart surgeryXx_NEWLINE_xXIf a patient has had surgery prior to enrolling on study, an enhanced MRI or CT scan should be done within 96 hours prior to surgery or at least 4-6 weeks after surgeryXx_NEWLINE_xXMajor injuries and/or surgery within the past ten days prior to start of study drugXx_NEWLINE_xXMajor surgery ? 28 days prior to enrollment.Xx_NEWLINE_xXIncomplete healing from previous surgery.Xx_NEWLINE_xXMinimal volume, non-disseminated disease, defined by the following:            \r\n* Residual tumor ? 1.5 cm^2 confirmed by MRI with contrast imaging within 21 days after surgery\r\n* No metastatic disease in the head, spine, or cerebrospinal fluid (CSF) confirmed by  both of the following:                \r\n** Enhanced MRI of the spine within 5 days before surgery OR within 28 days after surgery\r\n** Negative cytological examination of CSF after surgery, but before study enrollmentXx_NEWLINE_xXMajor surgical procedure (as defined by the local/lead site PI) within 28 days prior to the first dose of investigational product (IP); Note: local surgery of isolated lesions for palliative intent is acceptableXx_NEWLINE_xXPatients who have been hospitalized for infection or major surgery (e.g., requiring general anesthesia) within 2 weeks before registration or have not fully recovered from surgery are not eligible; Note: Subjects with surgical procedures conducted under local anesthesia may participateXx_NEWLINE_xXNegative urinalysis within 30 days prior to date of surgeryXx_NEWLINE_xXPatient has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these proceduresXx_NEWLINE_xXMajor surgery or trauma within 29 days prior to first dose of study drug and/or presence of any non-healing wound, fracture or ulcer (catheter placement is not major surgery)Xx_NEWLINE_xXPatients with any prior pelvic surgeryXx_NEWLINE_xXHave had prior major rectal surgery (except hemorrhoids).Xx_NEWLINE_xXPatient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effectsXx_NEWLINE_xXWomen who are currently undergoing or planning to undergo reconstruction surgery during the course of the study; women who have completed reconstruction surgery must be 30 days from surgeryXx_NEWLINE_xXPatient must consent for the appropriate surgeryXx_NEWLINE_xXPatients scheduled for surgery at Josie Robertson Surgery Center (JRSC)Xx_NEWLINE_xXNot scheduled for any major surgery during the anticipated study periodXx_NEWLINE_xXMajor surgery within 30 days prior to registrationXx_NEWLINE_xXPrior brain surgery =< 14 days prior to enrollmentXx_NEWLINE_xXMajor surgery/surgical therapy for any cause within 1 month prior to pasireotide administration; patients should have recovered and have a good clinical condition before entering the studyXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drug or incomplete recovery from any complications from surgery.Xx_NEWLINE_xXPatients with major surgery within 28 days prior to treatmentXx_NEWLINE_xXReceived major surgery (as defined by the Investigator), radiotherapy, or immunotherapy within 28 days of the first scheduled dose of MEDI7247.Xx_NEWLINE_xXMajor surgery within 28 days prior to enrollment.Xx_NEWLINE_xXMajor surgery within 28 days prior to enrollment.Xx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.Xx_NEWLINE_xXRevision surgery in women at least 18 years old with surgically absent breast tissue (previous reconstruction with silicone-filled or saline-filled implants or revision reconstruction requiring expansion surgery prior to surgery for study device implantation, with or without the use of human acellular dermal matrices (ADM), limited to AlloDerm® and FlexHD® PLIABLE, utilized in a prior surgery to expand tissue for study device placement)Xx_NEWLINE_xXPATIENT: Scheduled to undergo surgeryXx_NEWLINE_xXPatient must be willing to receive Nestle IMPACT Advance Recovery for five days prior to planned surgery as well as for 5 days after surgeryXx_NEWLINE_xXMajor open abdominal/thoracic surgery in the previous 30 days under general anesthesiaXx_NEWLINE_xXPHASE 0: Not yet had surgeryXx_NEWLINE_xXReconstructive surgeryXx_NEWLINE_xXSurgery or hospitalization within the last monthXx_NEWLINE_xXPrior surgery of the sacrumXx_NEWLINE_xXPatients taking anti-coagulants or other blood thinning medications prior to surgery during the specified time frames:\r\n* Low molecular weight heparin less than 36 hours prior to surgery\r\n* Coumadin less than 5 days prior to surgery\r\n* Plavix and NSAIDs less than 7 days prior to surgeryXx_NEWLINE_xXPatients on Celebrex less than 24 hours prior to surgeryXx_NEWLINE_xXScheduled surgery < 4 hrsXx_NEWLINE_xXScheduled surgery > 4 hrsXx_NEWLINE_xXPatient is planning major surgery within the next 6 monthsXx_NEWLINE_xXMost recent INR prior to surgery > 1.4Xx_NEWLINE_xXPrior H&N surgery excluding diagnostic procedures, transoral surgery, or non-radical neck dissectionXx_NEWLINE_xXPrevious prostate surgeryXx_NEWLINE_xXMajor injuries or surgery (e.g., craniotomy) < 28 days from the start of nintedanib/placebo administration; wound should be healed prior to starting therapyXx_NEWLINE_xXScheduled for major abdominal oncologic surgeryXx_NEWLINE_xXPatients must have recovered from prior surgeryXx_NEWLINE_xXAn interval of at least one year, but no more than five years, following the full completion of primary therapy for malignant disease; primary therapy is defined as:\r\n* Surgery plus radiation\r\n* Surgery plus chemotherapy\r\n* Surgery plus trastuzumab\r\n* Surgery plus hormone therapy\r\n** Note: For patients who receive hormone therapy following surgery, the definition of one-year post-completion of therapy is defined by the surgery date; patients who are currently receiving hormone therapy are eligible for enrollmentXx_NEWLINE_xXMajor surgery =< 28 days prior to registrationXx_NEWLINE_xXSurvival less than 12 months after surgery (either predicted survival before surgery or actual survival after surgery < 12 months)Xx_NEWLINE_xXScheduled for major surgery within the study periodXx_NEWLINE_xXSerum creatinine < 1.5 measured within 30 days of surgeryXx_NEWLINE_xXUncontrolled major psychiatric disorders, such as major depression or psychosisXx_NEWLINE_xXMajor surgery within 28 days prior to first dose of study drug.Xx_NEWLINE_xXMajor surgery within <=28 days prior to the first dose of ABBV-085.Xx_NEWLINE_xXMastectomy is the surgery performedXx_NEWLINE_xXPatients who have had major non-biopsy surgery in the last 20 days.Xx_NEWLINE_xXHave had major surgery within 30 days prior to the start of Day 1;Xx_NEWLINE_xXPatients who have not undergone surgery in the past 6 months; patients may have had neoadjuvant chemotherapy prior to surgeryXx_NEWLINE_xXPhysiologic suitability for major abdominal surgeryXx_NEWLINE_xXUse of dexmedetomidine within 28 days prior to day of surgeryXx_NEWLINE_xXCompleted surgeryXx_NEWLINE_xXUndergoing major surgeryXx_NEWLINE_xXMajor surgery within 30 days of day 1 of trialXx_NEWLINE_xXPrior sacral/lower spinal surgeryXx_NEWLINE_xXscheduled to be discharged the same day of surgeryXx_NEWLINE_xXSubjects may or may not have had surgery (lumpectomy or mastectomy) prior to RT; (NOTE: surgery is not required for eligibility)Xx_NEWLINE_xXContraindicated for surgery.Xx_NEWLINE_xXScheduled to be discharged the same day of surgeryXx_NEWLINE_xXMajor open abdominal/thoracic surgery in the previous 30 days under general anesthesia, except for TIVA (total intravenous anesthesia)Xx_NEWLINE_xXScheduled to undergo abdominal surgeryXx_NEWLINE_xXPreviously undergone major pelvic surgeryXx_NEWLINE_xXPatients with prior pancreatic surgery or cancersXx_NEWLINE_xXPatients with prior abdominal or pelvic surgeryXx_NEWLINE_xXPatients with any breast surgery or biopsy within 90 days prior to the studyXx_NEWLINE_xXPatients with any breast surgery or biopsy within 90 days prior to the studyXx_NEWLINE_xXMajor surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy] within the last 7 days prior to enrollment that may be associated with a risk of bleeding. Open biopsy is considered a major surgery.Xx_NEWLINE_xXMajor surgery within 14 days before enrollmentXx_NEWLINE_xXMajor abdominal or pelvic surgery within the past 6 monthsXx_NEWLINE_xXHistory of gastric surgeryXx_NEWLINE_xXPatient has had major surgery within 14 days prior to enrollmentXx_NEWLINE_xXHistory of baseline findings of: diabetes mellitus requiring insulin therapy; pancreatitis; hepatitis B, hepatitis C or HIV; malabsorption syndrome or inability to swallow or retain oral medicine; major surgery ? 28 days prior to enrollment; ECOG performance status ? 2; or another cancer within 3 years except for basal carcinoma of the skin or cervical carcinoma in situ; any clinically significant and uncontrolled major morbidityXx_NEWLINE_xXPatients may have received prior radiation therapy or major surgery; however, at least 21 days prior to treatment start must have elapsed since completion of radiation therapy or major surgery and patient must have recovered from all side effects at the time of randomizationXx_NEWLINE_xXMajor surgery within 28 days before Cycle 1 Day 1Xx_NEWLINE_xXMajor surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXPatients on blood thinners (aspirin or Coumadin) will be asked to stop medications 7 days prior to surgery; in the case of Coumadin, patients are switched to Lovenox 7 days prior to surgery and this is stopped the day before surgery; following surgery aspirin or Coumadin are recommenced 48 hours post operation (postop)Xx_NEWLINE_xXMajor surgery within 28 days of starting study treatment; there is no minimum time requirement for minor procedures such as biopsy or vascular access placementXx_NEWLINE_xXMajor surgery ? 28 days prior to the date of Randomization; patient must have complete recovery from surgeryXx_NEWLINE_xXHistory of surgery involving the luminal gastrointestinal (GI) tract, including bariatric surgery; exception: prior appendectomy is not an exclusion criterionXx_NEWLINE_xXWho are scheduled to undergo endoscopic or thoracic surgery surgeryXx_NEWLINE_xXIf subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMajor surgery within 14 days prior to start of study treatmentXx_NEWLINE_xXPatients who are cleared for surgeryXx_NEWLINE_xXPrior thoracic surgery on the same side of the lung as the SPN.Xx_NEWLINE_xXPrevious thoracic surgeryXx_NEWLINE_xXPatients who are unable to tolerate surgeryXx_NEWLINE_xXMajor surgery other than diagnostic surgery within 28 daysXx_NEWLINE_xXPrior anti-incontinence surgeryXx_NEWLINE_xXMajor surgery within four weeks prior to entry to the study (excluding placement of vascular access), or minor surgery (excluding tumor biopsies) within 14 days of first dose of study treatmentXx_NEWLINE_xXMajor surgery within 28 days of first drug doseXx_NEWLINE_xXCandidate for surgeryXx_NEWLINE_xXPrior hip replacement or other major pelvic surgeryXx_NEWLINE_xXPatients who have undergone surgery within 24 hours prior to the study sonographic examinationXx_NEWLINE_xXPatients who have undergone surgery within 24 hours prior to the study sonographic examinationXx_NEWLINE_xXContraindications for surgeryXx_NEWLINE_xXBe contraindicated for surgeryXx_NEWLINE_xXMajor surgery, including craniotomy, within 14 days before enrollmentXx_NEWLINE_xXAttempted maximal cytoreductive surgery; patients will still be eligible whether optimal or suboptimally debulked at the completion of the surgeryXx_NEWLINE_xXrecovered from any prior surgeryXx_NEWLINE_xXPatients who have already undergone any thyroid surgery will be excludedXx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.Xx_NEWLINE_xXPatients who require surgery sooner than 28 days from enrollmentXx_NEWLINE_xXSubjects undergoing a second surgery because they had positive margins in a previous surgery.Xx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.Xx_NEWLINE_xXMajor surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.Xx_NEWLINE_xXAny chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14 days.Xx_NEWLINE_xXMajor surgery . 28 days prior to enrollment.Xx_NEWLINE_xXMajor surgery (eg, laparotomy, thoracotomy or joint replacement) within 3 weeks prior to randomization or elective surgery scheduled to be performed during the study.Xx_NEWLINE_xXIf subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xX